Published in J Biol Response Mod on October 01, 1985
TLR-based immune adjuvants. Vaccine (2010) 2.10
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother (1995) 1.04
Toll-like receptors: the swiss army knife of immunity and vaccine development. Clin Transl Immunology (2016) 0.95
Influenza, immune system, and pregnancy. Reprod Sci (2014) 0.86
Broad-spectrum drugs against viral agents. Int J Mol Sci (2008) 0.81
Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother (1987) 0.79
Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death. Antimicrob Agents Chemother (1987) 0.76
TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair. PLoS One (2016) 0.75
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol (1996) 10.39
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Replication of semliki forest virus: three forms of viral RNA produced during infection. Proc Natl Acad Sci U S A (1966) 3.23
Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. J Immunol (1981) 3.15
Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2007) 3.12
Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1. J Immunol (1991) 2.80
Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study. Neurology (1996) 2.55
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Ataxia-telangiectasia. Medicine (Baltimore) (1972) 2.50
Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology (2011) 2.47
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology (2010) 2.29
Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature (1988) 2.27
The cost of delaying treatment in multiple sclerosis: what is lost is not regained. Neurology (2001) 2.27
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology (1998) 2.16
A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis (1975) 2.14
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann N Y Acad Sci (1966) 2.02
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
Inhibition of tumor growth by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.00
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol (1998) 1.97
Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature (1984) 1.95
Skewed T-cell receptor repertoire in genetically identical twins correlates with multiple sclerosis. Nature (1993) 1.89
Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab Invest (1981) 1.84
A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med (1991) 1.84
Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol (1995) 1.76
Multiple sclerosis (first of two parts). N Engl J Med (1982) 1.72
Molecular basis of the action of interferon. J Mol Biol (1968) 1.70
Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol (1983) 1.65
Correlates of posttraumatic epilepsy 35 years following combat brain injury. Neurology (2010) 1.62
Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A. J Immunol (1977) 1.58
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol (1993) 1.58
Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study. Neurology (1985) 1.57
Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell Immunol (1985) 1.52
Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol (1969) 1.51
Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol (1992) 1.50
Spinal cord injury: a 25-year morbidity and mortality study. Mil Med (1997) 1.45
Interferon preparations as modifiers of immune responses. Proc Soc Exp Biol Med (1972) 1.44
The recognition of viral RNA by mammalian ribosomes. An effect of interferon. Biochim Biophys Acta (1968) 1.44
Ribosomes: effect of interferon on their interaction with rapidly labeled cellular and viral RNA's. Science (1967) 1.44
Evidence of endogenous regulatory function of transforming growth factor-beta 1 in experimental allergic encephalomyelitis. Int Immunol (1992) 1.43
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med (1970) 1.42
Immunoglobulin A production in ataxia telangiectasia. Science (1965) 1.41
Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol (1992) 1.40
Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol (2000) 1.39
Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery (1996) 1.39
An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med (1970) 1.38
Immunoglobulin metabolism in ataxia telangiectasia. J Clin Invest (1968) 1.38
Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J x PL/J)F1 mice by myelin basic protein and its peptides: localization of a second encephalitogenic determinant. J Immunol (1983) 1.35
Prognosis of ocular myasthenia. Ann Neurol (1983) 1.35
Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis (1977) 1.33
Some factors affecting the interferon-induced antiviral state. Proc Soc Exp Biol Med (1967) 1.33
The germline repertoire of T cell receptor beta-chain genes in patients with chronic progressive multiple sclerosis. J Neuroimmunol (1989) 1.32
Glutaminase-free asparaginase from vibrio succinogenes: an antilymphoma enzyme lacking hepatotoxicity. Int J Cancer (1982) 1.32
Contact sensitivity in the pig. Immunology (1973) 1.30
Effect of interferon on early interferon production. Science (1966) 1.30
Induction of subacute murine measles encephalitis by monoclonal antibody to virus haemagglutinin. Nature (1981) 1.30
Interferon action on parental Semliki forest virus ribonucleic acid. J Virol (1967) 1.28
Immunological studies in tropical spastic paraparesis. Ann Neurol (1990) 1.26
Recurrent experimental allergic encephalomyelitis in the Lewis rat. J Immunol (1974) 1.26
Cell type-specific regulation of major histocompatibility complex (MHC) class I gene expression in astrocytes, oligodendrocytes, and neurons. Glia (1993) 1.25
A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1999) 1.24
Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine (2009) 1.24
Simian virus 40 Vp1 DNA-binding domain is functionally separable from the overlapping nuclear localization signal and is required for effective virion formation and full viability. J Virol (2001) 1.24
Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice. Lab Invest (1980) 1.24
Long-term experience with descending aortic dissection: the complication-specific approach. Ann Thorac Surg (1992) 1.23
Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Science (1973) 1.21
Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol (1993) 1.20
Relapsing murine experimental allergic encephalomyelitis induced by myelin basic protein. J Immunol (1983) 1.20
Lymph node function and lymphocyte circulation in the pig. Adv Exp Med Biol (1973) 1.20
An interdisciplinary method of classifying and monitoring medication errors. Am J Hosp Pharm (1985) 1.19
Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 1.19
Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J Neuroimmunol (1990) 1.18
The effect of polyinosinic-polycytidylic acid upon graft-vs-host activity in BALB/c mice. J Immunol (1970) 1.18
Thymic epithelial cell contains acetylcholine receptor. Lancet (1977) 1.18
Multiple sclerosis (second of two parts). N Engl J Med (1982) 1.18
Adoptively transferred chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Neuropathologic analysis. Lab Invest (1984) 1.17
Cytogenetic effects in human exposure to arsenic. Mutat Res (1997) 1.16
Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. J Immunol (1993) 1.15
Immune response of Lewis rats to peptide C1 (residues 68-88) of guinea pig and rat myelin basic proteins. J Exp Med (1977) 1.15
Interferon and uninfected cells. Proc Soc Exp Biol Med (1966) 1.15
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1997) 1.14
Immunological findings in neurological diseases associated with antibodies to HTLV-I: activated lymphocytes in tropical spastic paraparesis. Ann Neurol (1988) 1.14
Amyotrophic lateral sclerosis and parkinsonian syndromes in high incidence among the Auyu and Jakai people of West New Guinea. Neurology (1982) 1.13
Penicillamine-induced myasthenia gravis: effects of penicillamine on acetylcholine receptor. Neurology (1982) 1.13
Role of simian virus 40 Vp1 cysteines in virion infectivity. J Virol (2000) 1.12
Presentation of myelin basic protein by murine cerebral vascular endothelial cells. J Immunol (1985) 1.11
Intellectual function following penetrating head injury in Vietnam veterans. Brain (1988) 1.11
Chronologic neuropathology of relapsing experimental allergic encephalomyelitis in the mouse. Lab Invest (1982) 1.11
The effects of lateralized frontal lesions on mood regulation. Brain (1986) 1.11
Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet (1976) 1.10
Scrapie in immunologically deficient mice. Nature (1971) 1.10
The immune response against myelin basic protein in two strains of rat with different genetic capacity to develop experimental allergic encephalomyelitis. J Exp Med (1975) 1.09
Interferon: lack of detectable uptake by cells. Science (1966) 1.09
Modified polyriboinosinic-polyribocytidylic acid, an immunological adjuvant. Infect Immun (1976) 1.09
Interferon and interferon inducers in the treatment of malignancies. Arch Intern Med (1970) 1.08
Protective and toxic effects of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid on Venezuelan equine encephalomyelitis virus in rhesus monkeys. J Infect Dis (1979) 1.07
Human cellular immune response to measles virus polypeptides. J Virol (1984) 1.07